Communication clinical trials

Explore recruiting communication clinical trials.

Recruiting communication studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Communication trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

ALaDIN - Use of low doses of interleukin-2 in autism spectrum disorders

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Long-Term Extension Trial Investigating the Safety and Efficacy of GTX-102 in Patients with Angelman Syndrome

France, Spain, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 2, Open-label, Basket Study Investigating the Safety and Efficacy of GTX-102 in Adult and Pediatric Subjects with Deletion- or Nondeletion-type Angelman Syndrome

Portugal, Italy, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure – Chronic Kidney Disease (SAFE LAAC CKD). Comparative Health Effectiveness Ancillary Study – PILOT

Poland

Therapeutic use (Phase IV) EU CTIS Study details

Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in Bleeding Events following Left Atrial Appendage Closure (SAFE-LAAC). Comparative Health Effectiveness Randomized Trial – PILOT Study

Poland

Therapeutic use (Phase IV) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Sham-controlled Study Investigating the Efficacy and Safety of GTX-102 in Pediatric Subjects with Angelman Syndrome

Netherlands, Spain, Germany, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Communication trials by city

Communication in Toronto Communication in Vancouver Communication in Montreal Communication in Calgary Communication in Edmonton Communication in Ottawa Communication in Winnipeg Communication in Quebec City Communication in Hamilton Communication in Kitchener Communication in London Communication in Halifax Communication in New York Communication in Los Angeles Communication in Chicago Communication in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease